MannKind Corporation (MNKD)Healthcare | Biotechnology | Danbury, United States | NasdaqGM
3.19 USD
+0.17
(5.629%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 10:46 a.m. EDT
MannKind presents a classic biotech dilemma: a fortress of institutional interest and analyst optimism masking a fragile operational reality. The company boasts a 'strong buy' consensus and a massive 90% upside target, yet the fundamentals tell a story of a business struggling to turn a profit, with negative operating margins and a forward P/E that implies earnings won't materialize until 2027. The recent price action shows a slight recovery, but the stock remains trapped below its 200-day average, suggesting the market is skeptical of the immediate execution despite the hype. The options data confirms this tension. Traders are aggressively buying deep out-of-the-money calls for 2027 and beyond, betting on a massive clinical breakthrough or regulatory win that could re-rate the entire company. Simultaneously, there is significant put buying at near-term strikes, acting as a hedge against the inevitable volatility of a drug development cycle. This creates a high-risk environment where the stock is poised for a binary move rather than a steady climb. For the long-term investor, the lack of dividends and the history of volatile annual returns—despite a positive 9-year cumulative gain—highlight the difficulty of compounding here. The business has grown, but the path has been erratic. Until the company demonstrates sustained profitability and stabilizes its revenue growth away from one-off events, it remains a speculative vehicle suitable only for investors with a high tolerance for risk and a belief in the specific clinical outcomes of its pipeline. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.082040 |
| MSTL | 0.082814 |
| AutoARIMA | 0.084248 |
| AutoTheta | 0.085892 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 6.75 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.283 |
| Excess Kurtosis | -0.81 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 1.423 |
| Market Cap | 1,025,726,912 |
| Forward P/E | 25.02 |
| Beta | 1.08 |
| Profit Margins | -11.08% |
| Website | https://mannkindcorp.com |
As of Oct. 10, 2026, 10:46 a.m. EDT: Options activity reveals a distinct divergence between short-term hedging and long-term speculation. Near-term expirations show heavy put open interest at strikes above the current price (e.g., $4.00 and $5.00), indicating active protection against a drop toward the $2.23 low. However, the most aggressive positioning is found in long-dated calls (Jan 2027 and Feb 2028), where massive open interest accumulates at deep out-of-the-money strikes ($10.00 and $15.00). This suggests speculators are pricing in a binary event or a significant clinical catalyst capable of tripling the stock, while simultaneously buying insurance against a failure scenario.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.41681904 |
| Address1 | 1 Casper Street |
| All Time High | 121.55 |
| All Time Low | 0.67 |
| Ask | 5.03 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 4,569,210 |
| Average Daily Volume3 Month | 4,545,500 |
| Average Volume | 4,545,500 |
| Average Volume10Days | 4,569,210 |
| Beta | 1.082 |
| Bid | 2.93 |
| Bid Size | 2 |
| Board Risk | 2 |
| Book Value | -0.217 |
| City | Danbury |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 3 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.19 |
| Current Ratio | 1.719 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 3.2 |
| Day Low | 2.995 |
| Display Name | MannKind |
| Dividend Date | 1,488,499,200 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,960,000 |
| Earnings Call Timestamp Start | 1,785,960,000 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | 19,535,000 |
| Ebitda Margins | 0.049629997 |
| Enterprise To Ebitda | 69.026 |
| Enterprise To Revenue | 3.426 |
| Enterprise Value | 1,348,415,616 |
| Eps Current Year | 0.03 |
| Eps Forward | 0.1275 |
| Eps Trailing Twelve Months | -0.14 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.7472 |
| Fifty Day Average Change | -0.55719995 |
| Fifty Day Average Change Percent | -0.14869769 |
| Fifty Two Week Change Percent | -41.681904 |
| Fifty Two Week High | 6.51 |
| Fifty Two Week High Change | -3.3200002 |
| Fifty Two Week High Change Percent | -0.5099847 |
| Fifty Two Week Low | 2.23 |
| Fifty Two Week Low Change | 0.96000004 |
| Fifty Two Week Low Change Percent | 0.4304933 |
| Fifty Two Week Range | 2.23 - 6.51 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,091,021,400,000 |
| Float Shares | 297,601,937 |
| Forward Eps | 0.1275 |
| Forward P E | 25.01961 |
| Free Cashflow | 40,309,752 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 591 |
| Fullday Change | 0.18000007 |
| Fullday Change Percent | 5.9602675 |
| Fullday Price | 3.19 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.75386 |
| Gross Profits | 296,742,016 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.014680001 |
| Held Percent Institutions | 0.5711 |
| Implied Shares Outstanding | 321,544,484 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://www.mannkindcorp.com/investors-mannkind.aspx |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,488,499,200 |
| Last Split Factor | 1:5 |
| Long Business Summary | MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin. It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide. It has collaboration and license agreement with United Therapeutics Corporation; collaboration agreement with Thirona Bio, Inc. to evaluate the therapeutic for the treatment of pulmonary fibrosis; and licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. |
| Long Name | MannKind Corporation |
| Market | us_market |
| Market Cap | 1,025,726,912 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_9282918 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -43,614,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,209,007,259 |
| Number Of Analyst Opinions | 8 |
| Open | 3.02 |
| Operating Cashflow | -8,054,000 |
| Operating Margins | -0.00764 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Peg Ratio | 4.39 |
| Phone | 818 661 5000 |
| Previous Close | 3.02 |
| Price Eps Current Year | 106.333336 |
| Price Hint | 4 |
| Price To Book | -14.700461 |
| Price To Sales Trailing12 Months | 2.6058216 |
| Profit Margins | -0.1108 |
| Quick Ratio | 1.287 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | 0.17 |
| Regular Market Change Percent | 5.62914 |
| Regular Market Day High | 3.2 |
| Regular Market Day Low | 2.995 |
| Regular Market Day Range | 2.995 - 3.2 |
| Regular Market Open | 3.02 |
| Regular Market Previous Close | 3.02 |
| Regular Market Price | 3.19 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 3,756,529 |
| Return On Assets | 0.00794 |
| Revenue Growth | 0.429 |
| Revenue Per Share | 1.423 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 321,544,484 |
| Shares Percent Shares Out | 0.0813 |
| Shares Short | 26,157,578 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 26,554,857 |
| Short Name | MannKind Corporation |
| Short Percent Of Float | 0.082399994 |
| Short Ratio | 5.7 |
| Source Interval | 15 |
| State | CT |
| Symbol | MNKD |
| Target High Price | 13.0 |
| Target Low Price | 4.75 |
| Target Mean Price | 7.84375 |
| Target Median Price | 7.5 |
| Total Cash | 111,130,000 |
| Total Cash Per Share | 0.346 |
| Total Debt | 433,831,008 |
| Total Revenue | 393,628,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.14 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.86605 |
| Two Hundred Day Average Change | -0.67604995 |
| Two Hundred Day Average Change Percent | -0.17486839 |
| Type Disp | Equity |
| Volume | 3,756,529 |
| Website | https://mannkindcorp.com |
| Zip | 6,810 |